» Articles » PMID: 18074111

Association of Polymorphism in the Thermolabile 5, 10-methylene Tetrahydrofolate Reductase Gene and Hyperhomocysteinemia with Coronary Artery Disease

Overview
Publisher Springer
Specialty Biochemistry
Date 2007 Dec 13
PMID 18074111
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To determine the incidence of methylene tetrahydrofolate reductase (MTHFR) gene 677C-->T polymorphism and plasma homocysteine (Hcy) levels in a group of subjects who underwent coronary angiography, in an attempt to establish a correlation between these parameters and the severity of coronary artery disease (CAD) and to investigate the correlation between hyperhomocysteinemia (HHcy) and the presence of 677C-->T polymorphism.

Background: Elevated plasma Hcy level is an independent risk factor for CAD. A common mutation (677C-->T) in the gene coding for MTHFR has been reported to reduce the enzymatic activity and is associated with elevated levels of Hcy, especially in subjects with low folate intake.

Methods: The study group comprised of 84 patients with CAD and 100 age-and-sex matched controls who had no history or clinical evidence of CAD and/or MI. DNA was extracted from peripheral blood and genotypes were determined by polymerase chain reaction, restriction mapping with Hinf1, and gel electrophoresis. Conventional risk factors for CAD were prospectively documented.

Results: Allele and genotype frequencies in cases and control subjects were compatible with Hardy-Weinberg equilibrium. The frequencies of TT, CT, and CC genotypes among CAD patients were 4.8, 27.4, and 67.8% and in controls were 1.0, 19.0, and 80%. Hcy levels were higher in patients with triple-vessel disease compared to single and double vessel disease (P = 0.002). Multivariate analyses identified HHcy, diabetes mellitus, and hypertension as the independent predictors of CAD.

Conclusions: HHcy appears to have a graded effect on the risk of CAD as well as the severity and extent of coronary atherosclerosis. Our findings support that homozygous genotype of MTHFR is a genetic risk factor for CAD. A further study with larger sample size including assessment of vitamin status is needed to better clarify the relationship between MTHFR genotypes and CAD.

Citing Articles

Evaluating the Association Between Methylenetetrahydrofolate Reductase (Rs1801131 and Rs1801133) Gene Polymorphisms and Severity of Coronary Lesions in Patients With STEMI and NSTEMI: A Retrospective Cross-Sectional Study.

Nazarzadeh B, Ghazanfari S, Karimi F, Moezibady S, Salmani F, Dastjerdi K Health Sci Rep. 2025; 8(1):e70284.

PMID: 39807484 PMC: 11725607. DOI: 10.1002/hsr2.70284.


Biochemical Association of MTHFR C677T Polymorphism with Myocardial Infarction in the Presence of Diabetes Mellitus as a Risk Factor.

Mallhi T, Shahid M, Rehman K, Khan Y, Alanazi A, Alotaibi N Metabolites. 2023; 13(2).

PMID: 36837870 PMC: 9958922. DOI: 10.3390/metabo13020251.


Explore the Role of the rs1801133-PPARG Pathway in the H-type Hypertension.

Liang X, He T, Gao L, Wei L, Rong D, Zhang Y PPAR Res. 2022; 2022:2054876.

PMID: 35356087 PMC: 8958104. DOI: 10.1155/2022/2054876.


Methylenetetrahydrofolate Reductase Gene rs1801133 and rs1801131 Polymorphisms and Essential Hypertension Risk: A Comprehensive Analysis.

Fan Y, Wu L, Zhuang W Cardiovasc Ther. 2022; 2022:2144443.

PMID: 35284002 PMC: 8888071. DOI: 10.1155/2022/2144443.


Association Between Polymorphisms and the Risk of Essential Hypertension: An Updated Meta-analysis.

Meng H, Huang S, Yang Y, He X, Fei L, Xing Y Front Genet. 2021; 12:698590.

PMID: 34899823 PMC: 8662810. DOI: 10.3389/fgene.2021.698590.


References
1.
Morita H, Taguchi J, Kurihara H, Kitaoka M, Kaneda H, Kurihara Y . Genetic polymorphism of 5,10-methylenetetrahydrofolate reductase (MTHFR) as a risk factor for coronary artery disease. Circulation. 1997; 95(8):2032-6. DOI: 10.1161/01.cir.95.8.2032. View

2.
van Bockxmeer F, Mamotte C, Vasikaran S, Taylor R . Methylenetetrahydrofolate reductase gene and coronary artery disease. Circulation. 1997; 95(1):21-3. DOI: 10.1161/01.cir.95.1.21. View

3.
Wald N, Watt H, Law M, Weir D, McPartlin J, Scott J . Homocysteine and ischemic heart disease: results of a prospective study with implications regarding prevention. Arch Intern Med. 1998; 158(8):862-7. DOI: 10.1001/archinte.158.8.862. View

4.
Mager A, Lalezari S, Shohat T, Birnbaum Y, Adler Y, Magal N . Methylenetetrahydrofolate reductase genotypes and early-onset coronary artery disease. Circulation. 1999; 100(24):2406-10. DOI: 10.1161/01.cir.100.24.2406. View

5.
Chambers J, Ireland H, Thompson E, Reilly P, Obeid O, Refsum H . Methylenetetrahydrofolate reductase 677 C-->T mutation and coronary heart disease risk in UK Indian Asians. Arterioscler Thromb Vasc Biol. 2000; 20(11):2448-52. DOI: 10.1161/01.atv.20.11.2448. View